Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential

被引:121
作者
Colucci, Marie A. [1 ]
Moody, Christopher J. [1 ]
Couch, Gavin D. [1 ]
机构
[1] Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England
关键词
D O I
10.1039/b715270a
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
The quinone reductase enzyme NAD(P)H: quinone oxidoreductase 1 (NQO1) is a ubiquitous flavoenzyme that catalyzes the two-electron reduction of quinones. This Perspective briefly reviews the structure and mechanism, physiological role, and upregulation and induction of the enzyme, but focuses on the synthesis of new heterocyclic quinones and their metabolism by recombinant human NQO1. Thus a range of indolequinones, some of which are novel analogues of mitomycin C, benzimidazolequinones, benzothiazolequinones and quinolinequinones have been prepared and evaluated, leading to detailed knowledge of the structural requirements for efficient metabolism by the enzyme. Potent mechanism-based inhibitors (suicide substrates) of NQO1 have also been developed. These indolequinones irreversibly alkylate the protein, preventing its function both in standard enzyme assays and also in cells. Some of these quinones are also potent inhibitors of growth of human pancreatic cancer cells, suggesting a potential role for such compounds as therapeutic agents.
引用
收藏
页码:637 / 656
页数:20
相关论文
共 99 条
[31]   Development of novel quinone phosphorodiamidate prodrugs targeted to DT-diaphorase [J].
Flader, C ;
Liu, JW ;
Borch, RF .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (16) :3157-3167
[32]   Structures of mammalian cytosolic quinone reductases [J].
Foster, CE ;
Bianchet, MA ;
Talalay, P ;
Faig, M ;
Amzel, LM .
FREE RADICAL BIOLOGY AND MEDICINE, 2000, 29 (3-4) :241-245
[33]  
Franck R. W., 1990, CHEM ANTITUMOR AGENT, P379
[34]   Novel quinolinequinone antitumor agents:: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1) [J].
Fryatt, T ;
Pettersson, HI ;
Gardipee, WT ;
Bray, KC ;
Green, SJ ;
Slawin, AMZ ;
Beall, HD ;
Moody, CJ .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (07) :1667-1687
[35]   Novel quinolinequinone antitumor agents:: Structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1) [J].
Fryatt, T ;
Goroski, DT ;
Nilson, ZD ;
Moody, CJ ;
Beall, HD .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (15) :2195-2198
[36]   Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90 [J].
Ge, Jie ;
Normant, Emmanuel ;
Porter, James R. ;
Ali, Janid A. ;
Dembski, Marlene S. ;
Gao, Yun ;
Georges, Asimina T. ;
Grenier, Louis ;
Pak, Roger H. ;
Patterson, Jon ;
Sydor, Jens R. ;
Tibbitts, Thomas T. ;
Tong, Jeffrey K. ;
Adams, Julian ;
Palombella, Vito J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (15) :4606-4615
[37]   Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1:: Role of 17-AAG hydroquinone in heat shock protein 90 inhibition. [J].
Guo, WC ;
Reigan, P ;
Siegel, D ;
Zirrolli, J ;
Gustafson, D ;
Ross, D .
CANCER RESEARCH, 2005, 65 (21) :10006-10015
[38]  
Gustafson DL, 1996, MOL PHARMACOL, V50, P728
[39]   The role of NAD(P)H oxidoreductase (DT-diaphorase) in the bioactivation of quinone-containing antitumor agents: A review [J].
Gutierrez, PL .
FREE RADICAL BIOLOGY AND MEDICINE, 2000, 29 (3-4) :263-275
[40]  
Harding MM, 1997, CURR MED CHEM, V4, P405